Regulatory decisions affecting biopharma products in development, including: Abbvie, Agenus, Algernon, Alnylam, Anheart, Astrazeneca, Aurinia, Bellerophon, Biocryst, Bluebird, Can-Fite, Cansino, Cstone, Cytodyn, Cytokinetics, Dicerna, Eiger, Eisai, Eli Lilly, Exelixis, Genentech, Gilead Sciences, Hansoh, Helsinn, Humanigen, Immunomic, Immutep, Inmed, Intelgenx, Intercept, Intrabio, Janssen, Jazz, Kadmon, Kempharm, Lupin, Mallinckrodt, Mylan, Neuren, Newron, Nicox, Novartis, Orchard, Orion, Paratek, Pfizer, Pharming, Pharnext, Recordati, Sage, Sanofi, Seelos, Spero, Synairgen, Takeda, Teva, Trevena, Valneva, Virometix, Zai Lab, Zealand, Zydus Cadila.